Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A clinical trial of Coronary Covered Stents System for the treatment of coronary artery perforation.
This is a pre-market clinical investigation aiming to evaluate the safety and effectiveness of Coronary Covered Stents System for the treatment of coronary artery perforation.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental Arm | Experimental | Subjects in experimental group will be implanted with the Coronary Covered Stents System manufactured by Shanghai MicroPort Medical (Group) Co., Ltd. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| the Coronary Covered Stents System manufactured by Shanghai MicroPort Medical (Group) Co., Ltd. | Device | the Coronary Covered Stents System contains a covered stent and a delivery system |
| Measure | Description | Time Frame |
|---|---|---|
| Procedural Success | Successful implantation of a coronary covered stent and sealing of the perforation with ≤30% diameter stenosis(visual inspection) and TIMI III with no blood spillage requiring urgent surgical intervention. | During hospitalization (up to 7 days after procedure) |
| Measure | Description | Time Frame |
|---|---|---|
| Sealing Success | No residual blood spillage requiring urgent surgical intervention after successful release of the stent delivery system | Index procedure |
| Clinical Success | on the basis of procedure success with no device-related composite endpoint events during hospitalization (up to 7 days after procedure) |
Not provided
General Inclusion Criteria
Angiography Inclusion Criteria
General Exclusion Criteria
Angiographic Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ruifen Cao, M.M. | Contact | 0086-021-38954600 | 8102 | RuiFen.Cao@microport.com |
| Name | Affiliation | Role |
|---|---|---|
| Qian Tong, M.D. | The First Hospital of Jilin University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The First Hospital of Jilin University | Recruiting | Changchun | Jilin | 130061 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| During hospitalization (up to 7 days after procedure) |
| Mortality | Mortality (Cardiac, cardiovascular, non-cardiovascular) | 1 month, 6 months, and 1 year postoperatively |
| Myocardial Infarction | As per Myocardial Infarction (Fourth Universal Definition of Myocardial Infarction) types 1, 2 and 3 MI: have the clinical evidence of acute myocardial ischaemia and with detection of a rise and/or fall of cTn values with at least one value above the 99th percentile URL and at least one of the following:
types 4 and 5 MI: Coronary procedure-related MI ≤ 48 hours after the index procedure is arbitrarily defined by an elevation of cTn values > 5 times for type 4a MI and > 10 times for type 5 MI of the 99th percentile URL in patients with normal baseline values. | 1 month, 6 months, and 1 year postoperatively |
| Target Lesion Revascularization | Target Lesion Revascularization (ischemia-driven, non ischemia-driven) | 1 month, 6 months, and 1 year postoperatively |
| Target Vessel Revascularization | Target Vessel Revascularization (ischemia-driven, non ischemia-driven) | 1 month, 6 months, and 1 year postoperatively |
| Rate of emergency surgery or additional pericardial tamponade/puncture postoperatively | the rate of events caused an emergency surgery, additional pericardial tamponade or puncture postoperatively | 1 month, 6 months, and 1 year postoperatively |
| Stent thrombosis rate | s (by Academic Research Consortium [ARC] definitions) | 1 month, 6 months, and 1 year postoperatively |
| AEs and SAEs | Adverse Events and Severe Adverse Events | 1 month, 6 months, and 1 year postoperatively |